Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) — Working Capital to Net Assets Ratio
Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) has a Working Capital to Net Assets ratio of 10.2% as of June 2026. Working capital of CN¥317.16 Million (current assets of CN¥2.63 Billion minus current liabilities of CN¥2.31 Billion) is measured against net assets of CN¥3.10 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Sinopep-Allsino Biopharmaceutical Co. Lt defensive interval ratio to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Working Capital to Net Assets (2013–2025)
This chart shows how Sinopep-Allsino Biopharmaceutical Co. Ltd. A's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2013 to 2025. As of June 2026, the ratio stands at 10.2%, reflecting working capital of CN¥317.16 Million against net assets of CN¥3.10 Billion CNY. For the complete balance sheet picture, see Sinopep-Allsino Biopharmaceutical Co. Lt assets under control.
Annual Working Capital to Net Assets for Sinopep-Allsino Biopharmaceutical Co. Ltd. A (2013–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Sinopep-Allsino Biopharmaceutical Co. Ltd. A from 2013 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check 688076 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 11.6% | CN¥349.12 Million | CN¥3.00 Billion | CN¥2.51 Billion | CN¥2.16 Billion | ▲ +2.2 pp |
| 2024 | 9.4% | CN¥252.82 Million | CN¥2.68 Billion | CN¥2.01 Billion | CN¥1.75 Billion | ▼ -14.4 pp |
| 2023 | 23.8% | CN¥521.43 Million | CN¥2.19 Billion | CN¥1.49 Billion | CN¥973.34 Million | ▼ -2.2 pp |
| 2022 | 26.0% | CN¥501.15 Million | CN¥1.92 Billion | CN¥1.05 Billion | CN¥551.32 Million | ▼ -19.8 pp |
| 2021 | 45.8% | CN¥828.71 Million | CN¥1.81 Billion | CN¥1.10 Billion | CN¥275.40 Million | ▲ +34.9 pp |
| 2020 | 10.9% | CN¥105.70 Million | CN¥966.02 Million | CN¥487.91 Million | CN¥382.21 Million | ▲ +15.8 pp |
| 2019 | -4.8% | CN¥-40.56 Million | CN¥838.98 Million | CN¥293.73 Million | CN¥334.30 Million | ▼ -18.5 pp |
| 2018 | 13.7% | CN¥107.63 Million | CN¥785.38 Million | CN¥357.67 Million | CN¥250.04 Million | ▲ +45.1 pp |
| 2017 | -31.4% | CN¥-100.93 Million | CN¥321.20 Million | CN¥183.31 Million | CN¥284.24 Million | ▲ +264.9 pp |
| 2016 | -296.3% | CN¥-103.57 Million | CN¥34.95 Million | CN¥21.59 Million | CN¥125.16 Million | ▼ -196.3 pp |
| 2015 | -100.0% | CN¥-73.30 Million | CN¥73.32 Million | CN¥50.06 Million | CN¥123.35 Million | ▼ -879.9 pp |
| 2014 | 779.9% | CN¥-167.46 Million | CN¥-21.47 Million | CN¥5.59 Million | CN¥173.05 Million | ▲ +4860.3 pp |
| 2013 | -4080.4% | CN¥-150.38 Million | CN¥3.69 Million | CN¥12.74 Million | CN¥163.12 Million | — |